Literature DB >> 4512953

Daunorubicin in the therapy of acute granulocytic leukemia.

M Weil, O J Glidewell, C Jacquillat, R Levy, A A Serpick, P H Wiernik, J Cuttner, B Hoogstraten, L Wasserman, R R Ellison, S Gailani, K Brunner, R T Silver, V B Rege, M R Cooper, L Lowenstein, N I Nissen, F Haurani, J Blom, M Boiron, J Bernard, J F Holland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4512953

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  17 in total

Review 1.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 2.  Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.

Authors:  Peter H Wiernik
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

3.  A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.

Authors:  K Yamada; S Shirakawa; R Ohno; H Yamada; Y Hirota; K Ohara; K Yamagata; M Kobayashi; M Hirano; Y Ikeda
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 4.  Anthracyclines.

Authors:  Z Vanĕk; J Tax; I Komersová; P Sedmera; J Vokoun
Journal:  Folia Microbiol (Praha)       Date:  1977       Impact factor: 2.099

5.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.

Authors:  G Gahrton; M Björkholm; G Brenning; I Christenson; L Engstedt; S Franzén; B Gullbring; G Holm; C Högman; P Hörnsten; S Jameson; A Killander; C Simonsson-Lindemalm; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Paul; C Pauli; C Peterson; P Reizenstein; B Simonsson; K O Skårberg; A M Udén; B Wadman
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

7.  Uptake of the daunorubicin-DNA complex in cultured fibroblasts.

Authors:  C Peterson; G Noël; A Zenebergh; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 8.  Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Authors:  Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-08-30       Impact factor: 3.156

9.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.